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To the Editor: In a recent issue of Kidney International, Chen
et al.1 suggested that patients with myeloperoxidase (MPO)-
antineutrophil cytoplasmic autoantibodies (ANCA) positive
Wegener’s granulomatosis were not rare in Chinese, and the
prevalence of elevated initial serum creatinine was significantly
higher in patients with MPO-ANCA than that in patients with
PR3-ANCA. However, the possible contributors for more
prevalent elevated serum creatinine in patients with MPO-
ANCA were not clarified. First, the common confounding
factors associated with chronic kidney diseases (e.g. diabetes
mellitus, hypertension, advanced age, nephrotoxic agents (e.g.
non-steroid anti-inflammation drugs) use, etc.) and acute
renal failure (e.g. prerenal and postrenal types) should be
excluded in patients with elevated initial serum creatinine.
Second, the serum ANCA titer, a plausible indicator of disease
activity, might be further determined in both groups. Third,
the significantly lower prevalence of extra-renal involvement
(e.g. arthralgia, skin rash, ophthalmic, and ear involvement) in
the MPO-ANCA group1 may lead to a longer insidious
inflammation process, resulting in more severe renal damages
with elevated serum creatinine. It was speculated that MPO-
ANCA-positive Wegener’s granulomatosis was somewhat
more like microscopic polyangiitis, which was more likely to
have a greater degree and severity of glomerulosclerosis,
interstitial fibrosis, and tubular atrophy on initial renal
biopsy.2 In addition, the differences in histopathology between
MPO-ANCA and PR3-ANCA glomerulonephritis could be
explained by the observation that in patients with MPO-
ANCA, kidney biopsy was carried out late in the course of the
disease, and diffuse chronic sclerotic lesions predominated.3
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To the Editor: We read with interest the letter by
Rottembourg et al.1 Since long-acting nicotinic acid which
is a prodrug of nicotinamide has a long track record of safety,
we enrolled 34 hemodialysis patients in a prospective open
label study. After a pretrial washout of all other phosphate
binders, we gave a single dose of extended release nicotinic
acid (375 mg) along with meals. There was a significant
reduction of serum phosphate, calcium phosphate product
and alkaline phosphatase across the study group after 8 weeks
therapy as shown in Table 1.
Thrombocytopenia was not encountered in any of our
patients. Mild pruritus was seen in two patients. Hitherto
nicotinamide2,3 has been investigated in human and animal
studies. There are currently limited data on nicotinic acid.4
We conclude that nicotinic acid (vitamin B3) is a promising
agent for phosphate control in chronic kidney disease, due to
its low cost, established safety record and once daily dose
which will improve compliance. This agent holds promise for
most of the chronic kidney disease, patients in developing
nations who cannot afford sevelamer or lanthanum carbonate.
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Table 1 | Biochemical changes with nicotinic acid
Serum level
Prenicotinic
acid
Postnicotinic
acid P-value
Serum phosphorus (mg/dl) 7.771.5 5.671 o0.001
Serum calcium (mg/dl) 8.171.0 8.571.0 o0.015
Calcium phosphorus
product (mg2/dl2)
63.1715.1 48.7710.9 o0.001
Serum ALP (IU/l) 107766 82746 o0.001
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